News & Analysis on Clinical Trial Services & Contract Research And Development
Danish biopharma giant, Novo Nordisk is expanding its R&D Centre in China by introducing a new Diabetes Research unit and doubling its quota of employees from 100 to 200 by 2015.
A5 Laboratories has completed its CRO testing and analytical standard operating procedures (SOPs) ahead of schedule.
DSM’s microbial fermentation CMO business unit and UK-based biopharmaceutical company, PolyTherics, have formed an agreement to develop and manufacture PolyTherics’ lead ‘biobetter’ product, HiPEG IFN a-2a.
SOCMA CEO predicts reintroduction of rejected permanent R&D tax credit plan and urges Congress to act “sooner rather than later” to support US manufacturers.
Life Technologies has concluded license agreements, providing rights to its proprietary Chinese hamster ovary (CHO) cell lines for production of recombinant proteins used as therapeutic agents and vaccines.
In an exclusive Q&A Mark Rohlfing, Almac’s director of Quality, updates Outsourcing-pharma on the firm’s new North American HQ, growth plans and US recruitment drive.
The US FTC has given a positive advisory opinion to Rx-360’s shared audits and said the programme appears to offer “cognisable cost-saving and safety enhancing features”.